Quality of life and economic considerations in the management of prostate cancer
- PMID: 12751912
- DOI: 10.2165/00019053-200321080-00001
Quality of life and economic considerations in the management of prostate cancer
Abstract
The purpose of this article was to provide an overview of the morbidity and mortality of prostate cancer, QOL issues and the economic impact of the disease. We searched Medline (from 1990 onwards) for all studies dealing with prostate cancer epidemiology, treatment, screening and staging, and critically reviewed the most relevant articles, focusing on pharmacoeconomic issues. Prostate cancer is the most common cancer in men. In the US, new estimated cases of prostate cancer represented 14.8% of all new cancer cases for 2000, with estimated deaths from prostate cancer comprising 5.8% of all deaths from cancer. Current options for prostate cancer management include radical prostatectomy, cryosurgery, radiotherapy, hormone therapy and watchful waiting. Many of the long-term effects of treatment, such as urinary incontinence, impotence and radiation-induced proctitis, have a large impact on patients' quality of life and, in some patients, may offset the clinical benefits. Regulatory bodies and managed care organisations are assigning increasing importance to the evaluation of QOL benefits as an independent clinical endpoint and a measure of patient satisfaction. Several screening programmes for early detection of prostate cancer, mostly based on prostate-specific antigen (PSA) measurement or digital rectal examination, have been proposed, but their routine implementation in all asymptomatic elderly men has been questioned. There is still no definite proof that patient outcomes are improved by extensive PSA screening. Furthermore, the total cost of a screening programme is difficult to define since it extends well beyond the initial test. Several instruments are used for QOL assessment in prostate cancer, some of which have been specifically developed for, or adapted to, patients with this disease, such as the Functional Assessment Cancer Therapy (FACT) tool, Prostate Cancer Treatment Outcome Questionnaire (PCTO-Q) and Prostate Cancer Specific Quality of Life Instrument (PROSQOLI). More than 50% of treatment costs for prostate cancer are accrued during the patient's last year of life, and total initial care costs decrease with increasing age. In the US, initial average inpatient costs were estimated at $US 2253, in 1995, for men aged > or =80 years, compared with $US 4540 for men aged 35-64 years. In recent years, treatments based on combined modalities (i.e. radiotherapy/prostatectomy plus hormonal therapies) have emerged. Although cost-effectiveness analyses of various treatment options have been attempted, the strength of their conclusions appears to be limited by the lack of homogeneous literature data on the effects of such interventions on survival and morbidity.
Similar articles
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
-
Locally advanced prostate cancer: effective treatments, but many adverse effects.Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Prescrire Int. 2013. PMID: 23367679 Review.
-
Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.
-
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130995 Clinical Trial.
-
Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30. BJU Int. 2012. PMID: 22540922
Cited by
-
Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model.Electron Physician. 2015 Jun 5;7(2):1054-62. doi: 10.14661/2015.1054-1062. eCollection 2015 Apr-Jun. Electron Physician. 2015. PMID: 26120414 Free PMC article.
-
Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.Curr Oncol Rep. 2020 Feb 8;22(3):21. doi: 10.1007/s11912-020-0890-3. Curr Oncol Rep. 2020. PMID: 32036478 Review.
-
Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.Clinicoecon Outcomes Res. 2013 Jun 24;5:257-69. doi: 10.2147/CEOR.S44855. Print 2013. Clinicoecon Outcomes Res. 2013. PMID: 23836996 Free PMC article.
-
Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.World J Gastroenterol. 2013 Jan 14;19(2):185-98. doi: 10.3748/wjg.v19.i2.185. World J Gastroenterol. 2013. PMID: 23345941 Free PMC article. Review.
-
The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancer.Korean J Urol. 2010 May;51(5):308-12. doi: 10.4111/kju.2010.51.5.308. Epub 2010 May 19. Korean J Urol. 2010. PMID: 20495692 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous